-
1Academic Journal
Συγγραφείς: V. K. Tishchenko, V. V. Krylov, T. Yu. Kochetova, A. Yu. Shurinov, O. P. Vlasova, P. V. Shegai, S. A. Ivanov, A. D. Kaprin, В. К. Тищенко, В. В. Крылов, Т. Ю. Кочетова, А. Ю. Шуринов, О. П. Власова, П. В. Шегай, С. А. Иванов, А. Д. Каприн
Πηγή: Diagnostic radiology and radiotherapy; Том 15, № 4 (2024); 40-56 ; Лучевая диагностика и терапия; Том 15, № 4 (2024); 40-56 ; 2079-5343
Θεματικοί όροι: ПСМА-I&T, radioligand therapy, target radionuclide therapy, prostate-specific membrane antigen, PSMA, low-molecular-weight PSMA inhibitors, PSMA-617, PSMA-I&T, радиолигандная терапия, таргетная радионуклидная терапия, простат-специфический мембранный антиген, ПСМА, низкомолекулярные ингибиторы ПСМА, ПСМА-617
Περιγραφή αρχείου: application/pdf
Relation: https://radiag.bmoc-spb.ru/jour/article/view/1049/667; Каприн А.Д., Алексеев Б.Я., Матвеев В.Б. и др. Рак предстательной железы. Клинические рекомендации // Современная онкология. 2021. Т. 23, № 2. С. 211–247.; Попов С.В., Гусейнов Р.Г., Хижа В.В. и др. Рак предстательной железы: современная ситуация в России и г. Санкт-Петербурге по данным медико-статистических показателей // Онкоурология. 2023. T. 19, № 1. С. 102–114.; Song H., Guja K.E., Iagaru A. PSMA theragnostics for metastatic castration resistant prostate cancer // Trans. Oncol. 2022. Vol. 22. P. 101438. doi:10.1016/j.tranon.2022.101438.; Алексеев Б.Я., Нюшко К.М., Гафанов Р.А. и др. Эпидемиология и естественное течение неметастатического кастрационно-резистентного рака предстательной железы в российской популяции // Онкоурология. 2022. Т. 18, № 2. С. 111–122.; Vorster M., Sathekge M.M., Bott S.R.J., Ng K.L. Theranostics in Metastatic Castrate Resistant Prostate Cancer // Prostate Cancer [Internet]. Brisbane (AU): Exon Publications, 2021. Chapter 6. Рр. 81–96. doi:10.36255/exonpublications.prostatecancer.theranostics.2021.; Jeitner T.M., Babich J.W., Kelly J.M. Advances in PSMA theranostics // Transl. Oncol. 2022. Vol. 22. P. 101450. doi:10.1016/j.tranon.2022.101450.; AlSadi R., Bouhali O., Dewji S., Djekidel M. 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art // Oncologist. 2022. Vol. 27, No. 12. P. e957–e966. doi:10.1093/oncolo/oyac216.; Sartor O., de Bono J., Chi K.N. et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer // N. Engl. J. Med. 2021. Vol. 385, No. 12. P. 1091–1103. doi:10.1056/NEJMoa2107322.; Ferrier M.G., Radchenko V. An appendix of radionuclides used in targeted alpha therapy // J. Med. Imaging. Radiat Sci. 2019. Vol. 50. P. S58–S65. doi:10.1016/j.jmir.2019.06.051.; Chavoshi M., Mirshahvalad S.A., Metser U., Veit-Haibach P. 68Ga-PSMA PET in prostate cancer: a systematic review and meta-analysis of the observer agreement // Eur. J. Nucl. Med. Mol. Imaging. 2022. Vol. 49, No. 3. P. 1021–1029. doi:10.1007/s00259-021-05616-5.; Sathekge M., Bruchertseifer F., Vorster M., Morgenstern A., Lawal I.O. Global Experience with PSMA-based alpha therapy in prostate cancer // Eur. J. Nucl. Med. Mol. Imaging. 2021. Vol. 49. P. 30–46. doi:10.1007/s00259-021-05434-9.; Scher H.I., Morris M.J., Stadler W.M. et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 // J. Clin. Oncol. 2016. Vol. 34. P. 1402–1418. doi:10.1200/JCO.2015.64.2702.; Heinzel A., Boghos D., Mottaghy F.M. et al. 68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer // Eur. J. Nucl. Med. Mol. Imaging. 2019. Vol. 46. P. 1054–1062. doi:10.1007/s00259-019-4258-6.; Grubmuller B., Rasul S., Baltzer P. et al. Response assessment using [68Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castrationresistant prostate cancer // Prostate. 2020. Vol. 80. P. 74–82. doi:10.1002/pros.23919.; Fanti S., Goffin K., Hadaschik B.A. et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer // Eur. J. Nucl. Med. Mol. Imaging. 2021. Vol. 48, No. 2. P. 469–476. doi:10.1007/s00259-020-04934-4.; Lawal I.O., Mokoala K.M.G., Mahapane J. et al. A prospective intra-individual comparison of [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-NODAGA ZOL PET/CT, and [99mTc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases // Eur. J. Nucl. Med. Mol. Imaging. 2021. Vol. 48. P. 134–142. doi:10.1007/s00259-020-04867-y.; Kratochwil C., Bruchertseifer F., Giesel F.L. et al. 225Ac-PSMA-617 for PSMA-Targeted ɑ-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer // J. Nucl. Med. 2016. Vol. 57, No. 12. P. 1941–1944. doi:10.2967/jnumed.116.178673.; Kratochwil C., Bruchertseifer F., Rathke H. et al. Targeted ɑ-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding // J. Nucl. Med. 2017. Vol. 58, No. 10. P. 1624–1630. doi:10.2967/jnumed.117.191395.; Sathekge M.M., Lawal I.O., Bal C. et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study // Lancet Oncol. 2024. Vol. 25, No. 2. P. 175–183. doi:10.1016/S1470-2045(23)00638-1.; Sathekge M., Bruchertseifer F., Knoesen O. et al. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study // Eur. J. Nucl. Med. Mol. Imaging. 2019. Vol. 46, No. 1. P. 129–138. doi:10.1007/s00259-018-4167-0.; Sathekge M., Bruchertseifer F., Vorster M. et al. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy // J. Nucl. Med. 2020. Vol. 61, No. 1. P. 62–69. doi:10.2967/jnumed.119.229229.; Sathekge M., Bruchertseifer F., Vorster M. et al. mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis // J. Nucl. Med. 2022. Vol. 63, No. 10. P. 1496–1502. doi:10.2967/jnumed.121.263618.; Schlesinger M. Role of platelets and platelet receptors in cancer metastasis // J. Hematol. Oncol. 2018. Vol. 11, No. 1. P. 125. doi: https://doi.org/10.1186/s13045-018-0669-2.; Lawal I.O., Morgenstern A., Vorster M. et al. Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 ɑ-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer // Eur. J. Nucl. Med. Mol. Imaging. 2022. Vol. 49, No. 10. P. 3581–3592. doi:10.1007/s00259-022-05778-w.; Sathekge M., Bruchertseifer F., Vorster M. et al. 225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings // Eur. J. Nucl. Med. Mol. Imaging. 2023. Vol. 50, No. 7. P. 2210–2218. doi:10.1007/s00259-023-06165-9.; Bal C., Yadav M., Ballal S. et al. Clinical Experience on 225Ac-PSMA-617 Targeted Alpha Therapy in Metastatic Castration Resistant Prostate Cancer Patients: Safety and Efficacy Results // J. Nucl. Med. 2019. Vol. 60 (Suppl. 1). P. 462. https://jnm.snmjournals.org/content/60/supplement_1/462.; Yadav M.P., Ballal S., Sahoo R.K. et al. Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients // Theranostics. 2020. Vol. 10. P. 9364–9377. doi:10.7150/thno.48107.; Satapathy S., Mittal B.R., Sood A. et al. Health-related quality-of-life outcomes with Actinium-225-prostate-specific membrane antigen-617 therapy in patients with heavily pretreated metastatic castration-resistant prostate cancer // Indian J. Nucl. Med. 2020. Vol. 35. P. 299–304. doi:10.4103/ijnm.IJNM_130_20.; Sen I., Thakral P., Tiwari P. et al. Therapeutic efficacy of 225Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy // Ann. Nucl. Med. 2021. Vol. 35, No. 7. P. 794–810. doi:10.1007/s12149-021-01617-4.; Ballal S., Yadav M.P., Satapathy S. et al. Long term survival outcomes of salvage [225Ac]Ac PSMA 617 targetedalpha therapy in patients with PSMA expressing end stage metastatic castration resistant prostate cancer: a real world study // Eur. J. Nucl. Med. Mol. Imaging. 2023. Vol. 50. P. 3777–3789. doi:10.1007/s00259-023- 06340-y.; Ilhan H., Gosewisch A., Boning G. et al. Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC // Eur. J. Nucl. Med. Mol. Imaging. 2021. Vol. 48. P. 1262–1263. doi:10.1007/s00259-020-05023-2.; Zacherl M.J., Gildehaus F.J., Mittlmeier L. et al. First clinical results for PSMA-targeted ɑ-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients // J. Nucl. Med. 2021. Vol. 62. P. 669–674. doi:10.2967/jnumed.120.251017.; Khreish F., Ebert N., Ries M. et al. 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience // Eur. J. Nucl. Med. Mol. Imaging. 2020. Vol. 47. P. 721–728. doi:10.1007/s00259–019–04612–0.; Rosar F., Hau F., Bartholoma M. et al. Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy // Theranostics. 2021. Vol. 11. P. 4050–4060. doi:10.7150/thno.56211.; Rosar F., Krause J., Bartholomä M. et al. Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis // Pharmaceutics. 2021. Vol. 13, No. 5. P. 722. doi:10.3390/pharmaceutics13050722.; Kratochwil C., Bruchertseifer F., Rathke H. et al. Targeted ɑ-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control // J. Nucl. Med. 2018. Vol. 59, No. 5. P. 795–802. doi:10.2967/jnumed.117.203539.; Tauber R.L., Feuerecker B., Knorr K. et al. Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA // Ann. Oncol. 2019. Vol. 30. P. v342. doi: https://doi.org/10.1093/annonc/mdz248.029.; Van der Doelen M.J., Mehra N., van Oort I.M. et al. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy // Urol. Oncol. 2021. Vol. 39, No. 10. P. 729.e7–729.e16. doi:10.1016/j.urolonc.2020.12.002.; Feuerecker B., Tauber R., Knorr K. et al. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA // Eur. Urol. 2021. Vol. 79, No. 3. P. 343–350. doi:10.1016/j.eururo.2020.11.013.; Sanli Y., Kuyumcu S., Simsek D.H. et al. 225Ac-Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer: A Single-Center Experience // Clin. Nucl. Med. 2021. Vol. 46, No. 12. P. 943–951. doi:10.1097/RLU.0000000000003925.; Rupp N.J., Umbricht C.A., Pizzuto D.A. et al. First Clinicopathologic Evidence of a Non–PSMA-Related Uptake Mechanism for 68Ga-PSMA-11 in Salivary Glands // J. Nucl. Med. 2019. Vol. 60. P. 1270–1276. doi:10.2967/jnumed.118.222307.; Langbein T., Chausse G., Baum R.P. Salivary gland toxicity of PSMA radioligand therapy: Relevance and preventive strategies // J. Nucl. Med. 2018. Vol. 59. P. 1172–1173. doi:10.2967/jnumed.118.214379.; Satapathy S., Sood A., Das C.K., Mittal B.R. Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration resistant prostate cancer-a systematic review and meta-analysis // Prostate Cancer Prostatic Dis. 2021. Vol. 24, No. 3. P. 880–890. doi:10.1038/s41391-021-00349-w.; Yilmaz B., Nisli S., Ergul N. et al. Effect of external cooling on 177Lu-PSMA uptake by the parotid glands // J. Nucl. Med. 2019. Vol. 60. P. 1388–1393. doi:10.2967/jnumed.119.226449.; Harsini S., Saprunoff H., Alden T. et al. The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intraindividual imaging study // J. Nucl. Med. 2021. Vol. 62. P. 81–87. doi:10.2967/jnumed.120.246983.; Majer P., Jančařík A., Krecmerova M. et al. Discovery of Orally Available Prodrugs of the Glutamate Carboxypeptidase II (GCPII) Inhibitor 2-Phosphonomethylpentanedioic Acid (2-PMPA) // J. Med. Chem. 2016. Vol. 59, No. 6. P. 2810–2819. doi:10.1021/acs.jmedchem.6b00062.; Baum R.P., Langbein T., Singh A. et al. Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept // Nucl. Med. Mol. Imaging. 2018. Vol. 52, No. 1. P. 80–81. doi:10.1007/s13139-017-0508-3.; Mueller J., Langbein T., Mishra A., Baum R.P. Safety of High-Dose Botulinum Toxin Injections for Parotid and Submandibular Gland Radioprotection // Toxins. 2022. Vol. 14. P. 64. doi:10.3390/toxins14010064.; Rathke H., Kratochwil C., Hohenberger R. et al. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT // Eur. J. Nucl. Med. Mol. Imaging. 2019. Vol. 46. P. 139–147. doi:10.1007/s00259-018-4135-8.; Pelletier K., Côté G., Fallah-Rad N. et al. CKD after 225Ac-PSMA617 therapy in patients with metastatic prostate cancer // Kidney Int. Rep. 2021. Vol. 6. P. 853–856. doi:10.1016/j.ekir.2020.12.006.; Кочетова Т.Ю., Крылов В.В., Сигов М.А. и др. Пилотное исследование безопасности трех возрастающих активностей 225Ас-ПСМА для лечения метастатического кастрационно-резистентного рака предстательной железы // Онкологический журнал: лучевая диагностика, лучевая терапия. 2024. Т. 7, № 1. С. 30–40.; Майстренко Д.Н., Станжевский А.А., Важенина Д.А. и др. Радиолигандная терапия препаратами на основе радионуклида 225Ас: опыт Российского научного центра радиологии и хирургических технологий имени академика А.М. Гранова // Лучевая диагностика и терапия. 2022. Т. 13, № 4. С. 86–94.
-
2Academic Journal
Συγγραφείς: P. O. Rumyantsev, A. A. Bubnov, P. V. Sviridov, P. A. Nikiforovich, A. A. Trukhin, S. V. Korenev, П. О. Румянцев, А. А. Бубнов, П. В. Свиридов, П. А. Никифорович, А. А. Трухин, С. В. Коренев
Πηγή: Siberian journal of oncology; Том 20, № 4 (2021); 108-115 ; Сибирский онкологический журнал; Том 20, № 4 (2021); 108-115 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2021-20-4
Θεματικοί όροι: хирургия, molecular imaging, radio navigation, prostate cancer, prostate-specific membrane antigen, Cherenkov radiation, surgery, молекулярная визуализация, радионавигация, рак предстательной железы, простат-специфический мембранный антиген, черенковское излучение
Περιγραφή αρχείου: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/1872/890; Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019 Apr; 10(2): 63–89. doi:10.14740/wjon1191.; World Health Organization. Global cancer observatory: cancer today [Internet]. URL: https://gco.iarc.fr/today (cited 16.11.2020).; Pernar C.H., Ebot E.M., Wilson K.M., Mucci L.A. The Epidemiology of Prostate Cancer. Cold Spring Harb Perspect Med. 2018 Dec 3; 8(12): a030361. doi:10.1101/cshperspect.a030361.; Алексеев Б.Я., Каприн А.Д., Колонтарев К.Б.,Матвеев В.Б., Пушкарь Д.Ю., Раснер П.И., Харчилава Р.Р. Клинические рекомендации. Рак предстательной железы. 2018. 7.; Pieters B. Randomized trial for the evaluation of erectile dysfunction after whole or partial gland prostate brachytherapy. 2018. 25 p.; Chen F.Z., Zhao X.K. Prostate cancer: current treatment and prevention strategies. Iran Red Crescent Med J. 2013; 15(4): 279–84. doi:10.5812/ircmj.6499.; Vidal-Sicart S., Valdés Olmos R., Nieweg O.E, Faccini R., Grootendorst M.R., Wester H.J., Navab N., Vojnovic B., van der Poel H., Martínez-Román S., Klode J., Wawroschek F., van Leeuwen F.W.B. From interventionist imaging to intraoperative guidance: New perspectives by combining advanced tools and navigation with radio-guided surgery. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018 Jan-Feb; 37(1): 28–40. doi:10.1016/j.remn.2017.06.004.; Maurer T., Graefen M., van der Poel H., Hamdy F., Briganti A., Eiber M., Wester H.J., van Leeuwen F.W.B. Prostate-Specific Membrane Antigen-Guided Surgery. J Nucl Med. 2020; 61(1): 6–12. doi:10.2967/jnumed.119.232330.; Povoski S.P., Neff R.L., Mojzisik C.M., O'Malley D.M., Hinkle G.H., Hall N.C., Murrey D.A.Jr., Knopp M.V., Martin E.W.Jr. A comprehensive overview of radioguided surgery using gamma detection probe technology. World J Surg Oncol. 2009 Jan 27; 7: 11. doi:10.1186/1477-7819-7-11.; Parris C.C., Bigelow R.R., Francis J.E., Kelly G.G., Bell P.R. A Csi(Ti)-crystal surgical scintillation probe. Nucleonics. 1956; 14: 102–108.; Descotes J.L. Diagnosis of prostate cancer. Asian J Urol. 2019 Apr; 6(2): 129–136. doi:10.1016/j.ajur.2018.11.007.; Wawroschek F., Vogt H., Weckermann D., Wagner T., Harzmann R. The sentinel lymph node concept in prostate cancer – first results of gamma probe-guided sentinel lymph node identification. Eur Urol. 1999 Dec; 36(6): 595–600. doi:10.1159/000020054.; Silver D.A., Pellicer I., Fair W.R., Heston W.D., Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997 Jan; 3(1): 81–5.; Hovels A.M., Heesakkers R.A., Adang E.M., Jager G.J., Strum S., Hoogeveen Y.L., Severens J.L. , Barentsz J.O. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008; 63: 387–395.; De Visschere P.J.L., Standaert C., Fütterer J.J., Villeirs G.M., Panebianco V., Walz J., Maurer T., Hadaschik B.A., Lecouvet F.E., Giannarini G., Fanti S. A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer. Eur Urol Oncol. 2019 Feb; 2(1): 47–76. doi:10.1016/j.euo.2018.09.010.; van Leeuwen F.W.B., Winter A., van Der Poel H.G., Eiber M., Suardi N., Graefen M., Wawroschek F., Maurer T. Technologies for imageguided surgery for managing lymphatic metastases in prostate cancer. Nat Rev Urol. 2019 Mar; 16(3): 159–171. doi:10.1038/s41585-018-0140-8.; Litwin M.S., Tan H.J. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA. 2017; 317(24): 2532–2542. doi:10.1001/jama.2017.7248.; Wallitt K.L., Khan S.R., Dubash S., Tam H.H., Khan S., Barwick T.D. Clinical PET Imaging in Prostate Cancer. Radiographics. 2017 Sep-Oct; 37(5): 1512–1536. doi:10.1148/rg.2017170035.; Rauscher I., Krönke M., König M., Gafita A., Maurer T., Horn T., Schiller K., Weber W., Eiber M. Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy. J Nucl Med. 2020 Jan; 61(1): 51–57. doi:10.2967/jnumed.119.229187.; Maurer T., Robu S., Schottelius M., Schwamborn K., Rauscher I., van den Berg N.S., van Leeuwen F.W.B., Haller B., Horn T., Heck M.M., Gschwend J.E., Schwaiger M., Wester H.J., Eiber M. 99mTechnetiumbased Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer. Eur Urol. 2019 Apr; 75(4): 659–666. doi:10.1016/j.eururo.2018.03.013.; Watson A.A. The discovery of Cherenkov radiation and its use in the detection of extensive air showers. Nuclear Physics. 2011; 212–213: 13–19. doi:10.1016/j.nuclphysbps.2011.03.003.; Olde Heuvel J., de Wit-van der Veen B.J., Vyas K.N., Tuch D.S., Grootendorst M.R., Stokkel M.P.M., Slump C.H. Performance evaluation of Cerenkov luminescence imaging: a comparison of 68Ga with 18F. EJNMMI Phys. 2019 Oct 24; 6(1): 17. doi:10.1186/s40658-019-0255-x.; Olde Heuvel J., de Wit-van der Veen B.J., van der Poel H.G., Bekers E.M., Grootendorst M.R., Vyas K.N., Slump C.H., Stokkel M.P.M. 68Ga-PSMA Cerenkov luminescence imaging in primary prostate cancer: first-in-man series. Eur J Nucl Med Mol Imaging. 2020 Oct; 47(11): 2624–2632. doi:10.1007/s00259-020-04783-1.; Todd R., Nightingale J., Everett D. A proposed Gamma camera. Nature. 1974; 251: 132–134. doi:10.1038/251132a0.; Schonefelder V., Diehl R., Lichti G.G., Steinle H., Swanenburg B.N., Deerenberg A.J.M., Aarts H., Lockwood J., Webber W. The imaging Compton telescope COMPTEL on the gamma ray observatory. IEEE Trans. Nucl. Sci. 1984; 66–70. doi:10.1109/TNS.1984.4333363.; https://www.siboncoj.ru/jour/article/view/1872
-
3Academic Journal
Συγγραφείς: Тищенко В.К., Петриев В.М., Власова О.П., Крылов В.В., Шегай П.В., Иванов С.А., Каприн А.Д.
Πηγή: Ядерная физика и инжиниринг
Θεματικοί όροι: Prostate specific membrane antigen (PSMA), prostate cancer, monoclonal antibodies, low molecular weight PSMA inhibitors, простат-специфический мембранный антиген (ПСМА), рак предстательной железы, моноклональные антитела, низкомолекулярные ингибиторы ПСМА
Διαθεσιμότητα: https://repository.rudn.ru/records/article/record/100765/
-
4Academic Journal
Συγγραφείς: Тищенко В.К., Петриев В.М., Власова О.П., Панкратов А.А., Морозова Н.Б., Шегай П.В., Иванов С.А., Каприн А.Д.
Πηγή: Vestnik Rossiiskoi Akademii Meditsinskikh Nauk
Θεματικοί όροι: prostate-specific membrane antigen PSMA, technetium-99m, low molecular weight PSMA inhibitors, prostate cancer, single-photon emission computed tomography, простат-специфический мембранный антиген ПСМА, технеций-99m, низкомолекулярные ингибиторы ПСМА, рак предстательной железы, однофотонная эмиссионная компьютерная томография
Διαθεσιμότητα: https://repository.rudn.ru/records/article/record/99711/